MVASI™ IS APPROVED FOR THE TREATMENT OF 5 DIFFERENT CANCER TYPES1
For information about your specific diagnosis, please make a selection below:
YOUR DOCTOR HAS SAID THAT YOU HAVE A TYPE OF CANCER CALLED NON-SQUAMOUS NSCLC
NSCLC starts in your lungs. Like other cancers, it may grow and spread to other parts of your body.2
THERE ARE 2 MAIN TYPES OF LUNG CANCER: NON-SMALL CELL LUNG CANCER AND SMALL CELL LUNG CANCER2
The types of non-small cell lung cancer are named for the kinds of cells in which they occur and how the cells look under a microscope.3
make up about 40% of lung cancers. They usually occur in smokers and they are also the most common lung cancer seen in nonsmokers.2
Squamous cell (epidermoid) carcinomas
are a type of NSCLC usually found inside of the airways in the lungs.2
can be found anywhere in the lungs. They tend to grow and spread quickly, which can make them more difficult to treat.2
YOUR TREATMENT TEAM IS THERE TO HELP
Because NSCLC can impact you and your loved ones' lives, it is important to work closely with your treatment team. If you have questions, reach out to your doctor’s office directly for more information.
Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI™ by these organizations.
VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT NON-SMALL CELL LUNG CANCER (NSCLC)
Important Safety Information
Possible serious side effects
Everyone reacts differently to MVASI™ therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.
Most serious side effects (not common, but sometimes fatal):
Other possible serious side effects
Side effects seen most often
In clinical studies across different types of cancer, some patients experienced the following side effects:
MVASI™ is not for everyone
Talk to your doctor if you are:
If you have any questions about your condition or treatment, talk to your doctor.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.
Please see full Product Information for additional Important Safety Information.
Metastatic Colorectal Cancer (mCRC)
MVASI™ is approved to treat metastatic colorectal cancer (mCRC) for:
MVASI™ is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.
Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
MVASI™, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.
Recurrent Glioblastoma (rGBM)
MVASI™ is approved to treat recurrent glioblastoma in adults.
Metastatic Renal Cell Carcinoma (mRCC)
MVASI™, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).
Advanced Cervical Cancer (CC)
MVASI™, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.
References: 1. MVASI™ (bevacizumab-awwb) Prescribing Information, Amgen. 2. American Cancer Society. What is non-small cell lung cancer?Accessed June 8, 2019. 3. National Cancer Institute. Non-small cell lung cancer treatment - general information. Accessed June 8, 2019.